Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
Filed with ASX · · 8 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- AMP886 Activity in Acute Myeloid Leukemia
- CEO Resignation
- Amplia Receives $1.8m R&D Tax Incentive
- CEO & Managing Director Presentation to AGM
- First Patient Recruited to ACCENT Trial in Pancreatic Cancer
Later from Amplia Therapeutics
- Amplia Appoints Dr Christopher Burns CEO & Managing Director
- Appendix 4D and Financial Report Half Year ended 30 Sep 22
- Letter to Shareholders End of Year Summary and 2023 Plans
- Quarterly Activities and Cashflow Reports - December 2022
- First Patient Recruited to Cohort 2 of Accent Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics